Treatment of Leukemia Cutis in T-Cell Prolymphocytic Leukemia

Leukemia cutis — the infiltration of skin by leukemic cells — can arise in the setting of T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive mature T-cell malignancy.

Clinical scenario: Leukemia cutis occurring in a patient with T-cell prolymphocytic leukemia (T-PLL) — the most common type of mature T-cell leukemia — where skin involvement reflects systemic disease activity.

Treatment approach (partial)

In suitable patients, the approach involves a targeted anti-CD52 monoclonal antibody, with further consolidative intervention considered thereafter — but the full sequencing, eligibility criteria, and additional steps are detailed in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers15225393

The most common type of mature T-cell leukemia is T-cell prolymphocytic leukemia (T-PLL).

In suitable patients, a combination of anti-CD52 monoclonal antibody alemtuzumab followed by consolidation with allogeneic hematopoietic stem cell transplantation is currently the most effective treatment; however, the median survival is only 17 to 33 months in patients treated with alemtuzumab alone and 48 months in those with allogeneic stem cell transplantation.

View source ↗